On Today’s Calendar:
- nothing
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
Gapping down on weak earnings/guidance: MOLX -6.4%… Other news: ENCY -49.3% (FDA issues approvable letter, says development program for Thelin did not demonstrate the evidence of effectiveness needed for approval), CDNS -4.7% (NY Times reports buyout talks between Cadence Design Systems and two private equity firms appear to have stalled over price), X -2.5% (downgraded to Reduce at UBS), NMX -1.7% (CME says they are not currently in any discussion with NYMEX regarding a merger or acquisition).
Gapping Up
Gapping up on strong earnings/guidance: CMED +10.1%… M&A: AMK +42% (to be acquired by AVX for $24.75 per share, GCO +9.2% (to be acquired by FINL for $54.50 per share)… Other News: LXRX +24.3% (announces two agreements to finance long-term drug development strategy), VICL +14.9% (licensee AnGes MG announces positive results of Phase 3 angiogenesis trial in Japan), DDSS +8.7% (once-daily Tramadol approved for sale in Canada), ORCT +7.8% (Ma’ariv reports co is close to signing a contract worth about $40 mln with a new Japanese customer), CVTX +7.3% (positive Cramer mention), CRNT +4.5% (upgraded to Strong Buy at First Albany), STEM +4.5% (announces that Phase I clinical trial of HuCNS-SC has successfully completed enrollment), JSDA +3.4% (upgraded to Buy at ThinkEquity), ECIL (co confirms it is in discussions on possible takeover at $10/share), AA +2.6% (The Times reports BHP may consider a takeover).
Disclaimer & How I use this list
